Key Drivers
- Strong liquidity
- High returns
- Intangible concentration
AIAI Summary
Lantheus' strategic pivot to a focused radiopharma—centered on PYLARIFY reformulation and F‑18 launches—offers credible multi‑year upside, but the near‑term revenue/EPS reset, reimbursement and legal uncertainties, and execution risk on scaling TruVu/PYLARIFY mean investors should watch/hold until clear stabilization in PYLARIFY trends, successful launches, or improved guidance are demonstrated.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High returns
- •Intangible concentration
Lantheus delivers strong cash generation, high ROE/ROA and solid short‑term liquidity, but faces concentrated long‑term debt, heavy intangible‑asset risk and rich valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Mild uptrend
- •Stalled rallies
- •Quick pullbacks
Over the last month LNTH shows a modest ~3–4% gain with mild positive momentum, stalled near the low‑80s resistance and vulnerable to sharp pullbacks that could erase the short-term uptrend.
Sharp pullback from the 2026-03-10 peak into 2026-03-20 indicates short-term volatility and profit-taking risk
Sentiment & News
Key News Insights:
- •Regulatory wins
- •Investor interest
- •Legal scrutiny
Lantheus showed regulatory progress and renewed investor interest—driving a recent share uptick—while facing a delayed approval timeline for LNTH-2501 and a new legal/governance probe.
Regulatory approvals and investor inflows support near-term upside, but the PDUFA delay and litigation risk could increase volatility and weigh on sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings